These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16093276)

  • 1. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
    Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
    Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
    Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
    Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
    Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
    Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
    Klimm B; Eich HT; Haverkamp H; Lohri A; Koch P; Boissevain F; Trenn G; Worst P; Dühmke E; Müller RP; Müller-Hermelink K; Pfistner B; Diehl V; Engert A;
    Ann Oncol; 2007 Feb; 18(2):357-63. PubMed ID: 17071932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
    Bates NP; Williams MV; Bessell EM; Vaughan Hudson G; Vaughan Hudson B
    J Clin Oncol; 1994 Feb; 12(2):288-96. PubMed ID: 7509382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
    Anselmo AP; Cavalieri E; Osti FM; Cantonetti M; De Sanctis V; Alfo M; Amadori S; Enrici RM
    Anticancer Res; 2004; 24(6):4045-50. PubMed ID: 15736450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
    Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
    Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
    J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
    Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
    Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.
    Vlachaki MT; Ha CS; Hagemeister FB; Fuller LM; Rodriguez MA; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):609-16. PubMed ID: 9336140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
    Harris MA; Radford JA; Deakin DP; James RD; Swindell R; Cowan RA
    Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):53-7. PubMed ID: 14768756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.